Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (Crizanlizumab), With or Without Hydroxyurea/Hydroxycarbamide, in Sickle Cell Patients With Vaso-Occlusive Crisis

Trial Profile

A Phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (Crizanlizumab), With or Without Hydroxyurea/Hydroxycarbamide, in Sickle Cell Patients With Vaso-Occlusive Crisis

Recruiting
Phase of Trial: Phase II

Latest Information Update: 24 Jan 2019

At a glance

  • Drugs Crizanlizumab (Primary)
  • Indications Sickle cell anaemia
  • Focus Pharmacodynamics; Pharmacokinetics
  • Acronyms SOLACE-adults
  • Sponsors Novartis Pharmaceuticals
  • Most Recent Events

    • 15 Jan 2019 Planned End Date changed from 9 Nov 2020 to 5 Mar 2021.
    • 15 Jan 2019 Planned primary completion date changed from 9 Nov 2020 to 5 Mar 2021.
    • 01 Dec 2018 According to a Novartis media release, SOLACE-adults (A2202), SOLACE-kids (B2201), STAND (A2301), SUCCESSOR and SUSTAIN are a part of a "SENTRY program".
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top